{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T22:17:12Z","timestamp":1783203432379,"version":"3.54.6"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-13-164-01-CPPB"],"award-info":[{"award-number":["RSG-13-164-01-CPPB"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["7\/1\/2013-12\/30\/2019"],"award-info":[{"award-number":["7\/1\/2013-12\/30\/2019"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030364","name":"Community Foundation for Southeast Michigan","doi-asserted-by":"publisher","award":["10\/1\/2017-10\/31\/2020"],"award-info":[{"award-number":["10\/1\/2017-10\/31\/2020"]}],"id":[{"id":"10.13039\/100030364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006939","name":"Emory University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006710","name":"Wayne State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.urolonc.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:25:35Z","timestamp":1777580735000},"page":"307-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Specialty differences in treatment recommendations for low-risk prostate cancer"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-2783","authenticated-orcid":false,"given":"Jinping","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Janisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Ginsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathryn H.","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.urolonc.2026.04.002_bib0001","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN Clinical Practice guidelines in oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.002_bib0002","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamasurg.2017.1586","article-title":"Practice- vs physician-level variation in use of active surveillance for men with low-risk prostate cancer: implications for collaborative quality improvement","volume":"152","author":"Auffenberg","year":"2017","journal-title":"JAMA Surg"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.002_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.002_bib0004","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.clgc.2022.09.003","article-title":"Modern active surveillance in prostate cancer: a narrative review","volume":"21","author":"Pattenden","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.002_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40615-015-0109-8","article-title":"Racial differences in treatment decision-making for men with clinically localized prostate cancer: a population-based study","volume":"3","author":"Xu","year":"2016","journal-title":"J Racial Ethn Health Disparities"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.002_bib0006","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jamainternmed.2014.3021","article-title":"Physician variation in management of low-risk prostate cancer: a population-based cohort study","volume":"174","author":"Hoffman","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.002_bib0007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0272989X16662841","article-title":"Physician recommendations trump patient preferences in prostate cancer treatment decisions","volume":"37","author":"Scherr","year":"2017","journal-title":"Med Decis Making"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.002_bib0008","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/cncr.35190","article-title":"Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: the treatment options in prostate cancer study (TOPCS)","volume":"130","author":"Xu","year":"2024","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.002_bib0009","first-page":"211","article-title":"Cancer statistics for African Americans, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"10.1016\/j.urolonc.2026.04.002_bib0010","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1002\/cncr.27379","article-title":"Explaining racial differences in prostate cancer mortality","volume":"118","author":"Taksler","year":"2012","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.urolonc.2026.04.002_bib0011","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1001\/jama.2020.17020","article-title":"Association between African American race and clinical outcomes in men treated for low-risk prostate cancer with active surveillance","volume":"324","author":"Deka","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.002_bib0012","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/JU.0000000000000621","article-title":"African American race is not associated with risk of reclassification during active surveillance: results from the canary prostate cancer active surveillance study","volume":"203","author":"Schenk","year":"2020","journal-title":"J Urol"},{"issue":"21","key":"10.1016\/j.urolonc.2026.04.002_bib0013","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1056\/NEJMc1900333","article-title":"Active surveillance for low-risk prostate cancer in black patients","volume":"380","author":"Butler","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.002_bib0014","first-page":"468","article-title":"Men's perspectives on selecting their prostate cancer treatment","volume":"103","author":"Xu","year":"2011","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.urolonc.2026.04.002_bib0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.urology.2020.12.037","article-title":"Urologists' perceptions of active surveillance and their recommendations for low-risk prostate cancer patients","volume":"155","author":"Xu","year":"2021","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.002_bib0016","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/MLR.0000000000000155","article-title":"Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: results from a national survey of radiation oncologists and urologists","volume":"52","author":"Kim","year":"2014","journal-title":"Med Care"},{"issue":"24","key":"10.1016\/j.urolonc.2026.04.002_bib0017","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1001\/jama.283.24.3217","article-title":"Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer","volume":"283","author":"Fowler","year":"2000","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.002_bib0018","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/j.clgc.2019.01.008","article-title":"A national survey of radiation oncologists and urologists on perceived attitudes and recommendations of active surveillance for low-risk prostate cancer","volume":"17","author":"Kim","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"15","key":"10.1016\/j.urolonc.2026.04.002_bib0019","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.282.15.1458","article-title":"Why don't physicians follow clinical practice guidelines? A framework for improvement","volume":"282","author":"Cabana","year":"1999","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.002_bib0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11606-006-0075-2","article-title":"Sources of variation in physician adherence with clinical guidelines: results from a factorial experiment","volume":"22","author":"McKinlay","year":"2007","journal-title":"J Gen Intern Med"},{"issue":"15","key":"10.1016\/j.urolonc.2026.04.002_bib0021","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2004.06.020","article-title":"Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium","volume":"22","author":"Ayanian","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.002_bib0022","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3122\/jabfm.2012.06.120128","article-title":"Patient perspective on watchful waiting\/active surveillance for localized prostate cancer","volume":"25","author":"Xu","year":"2012","journal-title":"J Am Board Family Med: JABFM"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.002_bib0023","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/fampra\/cmw123","article-title":"Active surveillance for low-risk localized prostate cancer: what do men and their partners think?","volume":"34","author":"Mallapareddi","year":"2017","journal-title":"Fam Pract"},{"issue":"17","key":"10.1016\/j.urolonc.2026.04.002_bib0024","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.002_bib0025","doi-asserted-by":"crossref","first-page":"e1678","DOI":"10.1200\/OP.20.00929","article-title":"Understanding active surveillance for prostate cancer","volume":"17","author":"Lai","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.002_bib0026","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/JU.0000000000000031","article-title":"Active surveillance of prostate cancer is a viable option for men younger than 60 years","volume":"201","author":"Salari","year":"2019","journal-title":"J Urol"},{"issue":"17","key":"10.1016\/j.urolonc.2026.04.002_bib0027","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2016.68.0058","article-title":"Active surveillance in younger men with prostate cancer","volume":"35","author":"Leapman","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.04.002_bib0028","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2018.06.048","article-title":"Younger men with prostate cancer have lower risk of upgrading while on active surveillance: a meta-analysis and systematic review of the literature","volume":"121","author":"Mahran","year":"2018","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.002_bib0029","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.eururo.2025.06.012","article-title":"Active surveillance for screen-detected low- and intermediate-risk prostate cancer: extended follow-up up to 25 years in the GOTEBORG-1 trial","volume":"88","author":"Palmstedt","year":"2025","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.002_bib0030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.juro.2016.08.104","article-title":"Racial disparities in active surveillance for prostate cancer","volume":"197","author":"Krishna","year":"2017","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.002_bib0031","doi-asserted-by":"crossref","first-page":"432e1","DOI":"10.1016\/j.urolonc.2020.11.024","article-title":"Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer","volume":"39","author":"Liu","year":"2021","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.002_bib0032","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41391-021-00425-1","article-title":"Progression on active surveillance for prostate cancer in black men: a systematic review and meta-analysis","volume":"25","author":"Vigneswaran","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2026.04.002_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.644885","article-title":"Variation in the use of active surveillance for low-risk prostate cancer across US census regions","volume":"11","author":"Al Hussein Al Awamlh","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.002_bib0034","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/JU.0000000000001308","article-title":"Defining quality metrics for active surveillance: the Michigan urological surgery improvement collaborative experience","volume":"204","author":"Ginsburg","year":"2020","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.002_bib0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.eururo.2022.05.028","article-title":"The impact of a statewide active surveillance initiative: a roadmap for increasing active surveillance utilization nationwide","volume":"83","author":"Vince","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.04.002_bib0036","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.euros.2023.04.006","article-title":"Variations in the uptake of active surveillance for prostate cancer and its impact on outcomes","volume":"52","author":"Ahlberg","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.002_bib0037","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bju.13651","article-title":"Qualitative study on decision-making by prostate cancer physicians during active surveillance","volume":"120","author":"Loeb","year":"2017","journal-title":"BJU Int"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926002012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926002012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:56:58Z","timestamp":1783202218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926002012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1078143926002012"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specialty differences in treatment recommendations for low-risk prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}